Pharmacopoeia (IP, BP, USP & NF) Notes & MCQs for HPRCA Pharmacy Officer Exam
PHARMACOPOEIA
Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), United States Pharmacopeia (USP), National Formulary (NF) and Extra Pharmacopoeia
Himexam.com
- Introduction and meaning of Pharmacopoeia
- History and development of Pharmacopoeias
- Indian Pharmacopoeia (IP)
- British Pharmacopoeia (BP)
- United States Pharmacopeia (USP)
- National Formulary (NF)
- Extra Pharmacopoeia / Martindale
- Pharmacopoeial monographs and general chapters
- Important technical terms and reference standards
- Comparative tables, examination facts and MCQs
1. Introduction to Pharmacopoeia
A Pharmacopoeia is an official or authoritative reference publication that contains standards for the identity, purity, strength and quality of drugs and pharmaceutical substances. It provides approved specifications, analytical procedures and tests used to evaluate pharmaceutical materials and finished dosage forms.
In simple words, a pharmacopoeia tells us what quality a medicine must have and how that quality should be tested.
Meaning and origin of the word
- The word Pharmacopoeia is derived from Greek words.
- Pharmakon: Drug or medicine.
- Poiein: To make or prepare.
- Thus, Pharmacopoeia broadly refers to the preparation or making of medicines.
Objectives of Pharmacopoeia
- Standardisation: Establishes uniform standards for medicines.
- Identification: Provides tests to confirm the identity of a drug.
- Purity: Establishes acceptable limits for impurities and contaminants.
- Strength: Ensures that the drug contains the required amount of active ingredient.
- Quality control: Provides analytical procedures for testing raw materials and finished products.
- Safety and efficacy support: Helps ensure consistent pharmaceutical quality, which is essential for patient safety and reliable therapeutic performance.
- Regulatory compliance: Provides legally recognised standards where adopted by the relevant legislation.
Importance in Pharmacy
- Used in pharmaceutical manufacturing.
- Used in quality assurance (QA) and quality control (QC).
- Useful in drug testing laboratories.
- Helps regulatory authorities inspect the quality of medicines.
- Provides standard analytical methods for pharmacists and pharmaceutical scientists.
- Helps maintain consistency between different batches of a medicine.
2. Important Pharmacopoeias of the World
Several countries and regions publish pharmacopoeias to establish official standards for medicines. The most important publications for this examination are IP, BP, USP and NF.
| Abbreviation | Full Name | Country / Region |
|---|---|---|
| IP | Indian Pharmacopoeia | India |
| BP | British Pharmacopoeia | United Kingdom |
| USP | United States Pharmacopeia | United States |
| NF | National Formulary | United States |
| Ph. Eur. | European Pharmacopoeia | Europe |
| JP | Japanese Pharmacopoeia | Japan |
| Int. Ph. | International Pharmacopoeia | World Health Organization |
3. Indian Pharmacopoeia (IP)
The Indian Pharmacopoeia (IP) is the official book of standards for drugs manufactured and/or marketed in India. It is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health and Family Welfare, Government of India.
It contains authoritative specifications and analytical procedures for determining the identity, purity and strength of pharmaceutical substances and preparations.
3.1 Indian Pharmacopoeia Commission (IPC)
- Full name: Indian Pharmacopoeia Commission.
- Administrative ministry: Ministry of Health and Family Welfare, Government of India.
- Headquarters: Ghaziabad, Uttar Pradesh, India.
- Nature: Autonomous institution of the Government of India.
- Major function: Preparation, revision and publication of the Indian Pharmacopoeia.
- Other functions: Development of reference substances, publication of the National Formulary of India and training on pharmacopoeial standards.
3.2 History of Indian Pharmacopoeia
The development of Indian pharmacopoeial standards started during the British period and continued after India’s independence.
A committee of the East India Company’s Dispensary recommended the publication of a pharmacopoeia.
Bengal Pharmacopoeia and General Conspectus of Medicinal Plants was published, covering commonly used indigenous remedies.
Indian Pharmacopoeia was published, covering drugs from the British Pharmacopoeia 1867 and indigenous drugs used in India.
A supplement to the 1868 publication was issued, incorporating vernacular names of indigenous drugs and plants.
British Pharmacopoeia became officially recognised in India.
The Drugs Enquiry Committee recommended publication of a National Pharmacopoeia.
Indian Pharmacopoeia Committee was constituted after independence.
First official edition of Indian Pharmacopoeia was published.
Supplement to the first edition was published.
Second edition of IP was published.
Supplement to the second edition was published.
Third edition of IP was published.
Fourth edition of IP was published.
Indian Pharmacopoeia Commission was established as an autonomous institution by the Ministry of Health and Family Welfare.
Fifth edition of IP was published.
IPC became fully operational as an autonomous body on 1 January 2009.
Sixth edition of IP was published.
Seventh edition of IP was published.
Eighth edition of IP was published.
Ninth edition of IP was published and became effective from 1 December 2022.
Tenth edition of Indian Pharmacopoeia was published, superseding IP 2022.
3.3 Editions of Indian Pharmacopoeia – Quick Revision Table
| Edition | Year | Important Supplement / Addendum |
|---|---|---|
| First | 1955 | Supplement 1960 |
| Second | 1966 | Supplement 1975 |
| Third | 1985 | Addenda 1989 and 1991 |
| Fourth | 1996 | Addenda 2000, 2002 and 2005; Veterinary Supplement 2000 |
| Fifth | 2007 | Addendum 2008 |
| Sixth | 2010 | Addendum 2012 |
| Seventh | 2014 | Addenda 2015 and 2016 |
| Eighth | 2018 | Addenda 2019 and 2021 |
| Ninth | 2022 | Amendment lists issued subsequently |
| Tenth | 2026 | Amendments and updates as officially issued |
3.4 Legal Status of Indian Pharmacopoeia
- IP is recognised as the official book of drug standards in India.
- It is published in accordance with the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
- Its standards are legally recognised and enforced by regulatory authorities.
- The Second Schedule of the Drugs and Cosmetics Act, 1940 deals with standards for drugs.
- IP standards are used for quality assessment and may be relied upon in legal disputes concerning drug quality.
3.5 Contents of Indian Pharmacopoeia
Indian Pharmacopoeia contains general information, general notices, general chapters, monographs and reference information related to pharmaceutical quality.
Major categories include:
- Drug substances (active pharmaceutical ingredients).
- Dosage forms and pharmaceutical preparations.
- Pharmaceutical aids and excipients.
- Antibiotics and antimicrobial substances.
- Vaccines and immunological products.
- Blood and blood-related products.
- Biotechnology-derived therapeutic products.
- Herbal drugs and herbal products.
- Phytopharmaceuticals.
- Radiopharmaceutical preparations.
- Veterinary medicines.
- General tests, analytical procedures and reference data.
3.6 IP 2026 – Important Structural Facts
The tenth edition, IP 2026, is presented in four volumes.
3.7 IP Reference Substances (IPRS)
Indian Pharmacopoeia Reference Substances are official reference materials used for identification, testing and assay of pharmaceutical substances according to the requirements of IP.
- They are used as comparison standards in analytical procedures.
- They help verify the identity of a drug.
- They support the determination of purity and strength.
- They are used in quality-control laboratories.
- They provide reliable analytical reference material for pharmacopoeial testing.
3.8 National Formulary of India (NFI)
The National Formulary of India is published by the Indian Pharmacopoeia Commission. It is intended to promote rational use of medicines by providing information on drugs, their indications, dosage, precautions and appropriate use.
| Indian Pharmacopoeia (IP) | National Formulary of India (NFI) |
|---|---|
| Primarily establishes official quality standards. | Primarily provides information to support rational prescribing and use of medicines. |
| Contains monographs and analytical tests. | Contains therapeutic and prescribing information. |
| Used extensively in quality control and regulation. | Used by healthcare professionals for rational medicine use. |
Join our educational communities for pharmacy notes, examination updates and practice material.
Join Telegram Channel Join WhatsApp Channel4. British Pharmacopoeia (BP)
The British Pharmacopoeia (BP) is the official pharmacopoeia of the United Kingdom. It provides authoritative standards for pharmaceutical substances, medicinal products and preparations used in the UK.
4.1 Important Facts about BP
- Abbreviation: BP.
- Full name: British Pharmacopoeia.
- First published: 1864.
- Publishing authority: British Pharmacopoeia Commission, through the Medicines and Healthcare products Regulatory Agency (MHRA).
- Country: United Kingdom.
- Publication frequency: Annually.
- Usual publication time: August.
- Effective date: 1 January of the following year.
4.2 History of British Pharmacopoeia
- Before 1864, separate pharmacopoeias existed for London, Edinburgh and Dublin.
- The British Pharmacopoeia was first published in 1864.
- It aimed to establish uniform standards for medicines across the United Kingdom.
- The first edition brought together standards that had previously been published separately.
- The BP has been revised regularly to accommodate scientific and pharmaceutical developments.
4.3 British Pharmacopoeia Commission
The British Pharmacopoeia Commission is responsible for preparing and maintaining the British Pharmacopoeia with scientific and expert input. The MHRA publishes and maintains the BP.
4.4 Contents of BP
- General notices.
- General monographs.
- Specific monographs for drug substances.
- Monographs for excipients.
- Monographs for formulated preparations.
- Herbal drugs and herbal medicinal products.
- Blood-related products.
- Immunological products.
- Radiopharmaceutical preparations.
- Appendices and supplementary chapters.
- Infrared reference spectra and other reference information.
4.5 Relationship between BP and European Pharmacopoeia
The British Pharmacopoeia incorporates all monographs and texts of the European Pharmacopoeia (Ph. Eur.), along with national BP standards.
4.6 BP 2026 and BP 2027 – Current Facts
- BP 2026: Legally effective from 1 January 2026 to 31 December 2026.
- BP 2027: Published on 1 August 2026 and scheduled to become effective on 1 January 2027.
- BP 2026 contains approximately 4,000 monographs.
- BP 2026 incorporates the relevant European Pharmacopoeia texts and national standards.
5. United States Pharmacopeia (USP)
The United States Pharmacopeia is a compendium of official quality standards for medicines and their ingredients in the United States. It is developed and published by the United States Pharmacopeial Convention, an independent, scientific, non-profit organisation.
5.1 Important Facts about USP
- Full name: United States Pharmacopeia.
- Abbreviation: USP.
- First published: 1820.
- Country: United States of America.
- Publishing organisation: United States Pharmacopeial Convention.
- Nature: Independent, scientific, non-profit organisation.
- Purpose: Establishes public standards for the identity, strength, quality and purity of medicines and their ingredients.
5.2 History of USP
- In 1820, a group of physicians in the United States came together to address problems relating to inconsistent medicine quality.
- The first edition of USP was published in 1820.
- The aim was to establish uniform standards for medicinal substances and preparations.
- USP standards later received recognition under US federal drug legislation.
- The Federal Food, Drug, and Cosmetic Act of 1938 gave statutory recognition to official compendia including USP and NF.
5.3 Functions of USP
- Develops standards for pharmaceutical substances and products.
- Provides monographs for active pharmaceutical ingredients and finished dosage forms.
- Develops standards for pharmaceutical excipients.
- Provides general chapters containing analytical procedures and quality requirements.
- Develops reference standards used in laboratory testing.
- Supports global medicine quality and patient safety.
5.4 Main Contents of USP
- Monographs for drug substances.
- Monographs for finished drug products.
- Monographs for compounded preparations.
- Dietary supplement and ingredient standards.
- General chapters.
- General notices and requirements.
- Reference standards.
5.5 USP General Chapters
General chapters provide standard analytical methods, procedures, tests and technical requirements that may apply to multiple monographs.
In the USP-NF system, chapter numbering is important:
For example, USP General Chapter <711> deals with Dissolution and <701> deals with Disintegration.
6. National Formulary (NF)
The National Formulary is an American pharmaceutical compendium that historically focused on preparations and pharmaceutical ingredients not adequately covered by the USP.
6.1 Important Facts about NF
- Full name: National Formulary.
- First published: 1888.
- Original publisher: American Pharmaceutical Association (APhA).
- Original title: National Formulary of Unofficial Preparations.
- 1975: USP acquired NF and the two publications were combined under one cover.
- Current combined publication: United States Pharmacopeia–National Formulary (USP-NF).
6.2 USP and NF – Relationship
Historically, USP and NF were separate publications. USP mainly covered recognised medicinal substances and preparations, while NF initially covered unofficial preparations and later became particularly important for excipient standards.
Drug substances and products
Especially excipients
Combined compendium
6.3 What is USP-NF?
USP-NF is the combined publication of the United States Pharmacopeia and the National Formulary. Although they are published together and share general notices and requirements, USP and NF remain separate compendia.
| USP | NF |
|---|---|
| Standards for drug substances. | Particularly important for excipient standards. |
| Standards for dosage forms and drug products. | Standards for inactive pharmaceutical ingredients. |
| Includes standards for compounded preparations and dietary supplement ingredients. | Contains monographs for many pharmaceutical excipients. |
6.4 Examples of Pharmaceutical Excipients
- Lactose – diluent or filler.
- Starch – binder or disintegrant, depending on formulation.
- Magnesium stearate – lubricant.
- Talc – glidant or anti-adherent.
- Microcrystalline cellulose – diluent and binder.
- Carbomer – thickening and gelling agent.
- Sodium carboxymethylcellulose – thickening and suspending agent.
- Polysorbate 80 – surfactant.
7. Extra Pharmacopoeia – Martindale
The Extra Pharmacopoeia was a pharmaceutical reference publication that provided information on drugs, preparations and substances, including many that were not included in the British Pharmacopoeia.
It was developed by William Martindale and became an important reference source for pharmacists and medical professionals.
7.1 Important Historical Facts
- Author: William Martindale.
- First edition: 1883.
- Original title: The Extra Pharmacopoeia of Unofficial Drugs and Chemical and Pharmaceutical Preparations.
- Co-author of first edition: Dr. W. Wynn Westcott.
- First edition length: 313 pages.
- 1972: Renamed Martindale: The Extra Pharmacopoeia.
- 1999: Renamed Martindale: The Complete Drug Reference.
- Current publisher: Pharmaceutical Press, the knowledge business of the Royal College of Pharmacy.
7.2 Why Was It Called Extra Pharmacopoeia?
In its early editions, the word “Extra” referred to its coverage of drugs and substances that were not included in the British Pharmacopoeia.
7.3 Contents of Martindale
- Drug information and monographs.
- Therapeutic uses and indications.
- Pharmacological actions.
- Adverse effects.
- Drug interactions.
- Contraindications and precautions.
- Dosage and administration information.
- Information about pharmaceutical preparations available in different countries.
- Information on herbal medicines and other medicinal substances.
7.4 Importance of Extra Pharmacopoeia
- Provides detailed drug information beyond official pharmacopoeial specifications.
- Useful for pharmacists, physicians and pharmaceutical professionals.
- Helps in understanding drug uses, adverse reactions and interactions.
- Useful for comparing medicinal preparations available in different countries.
7.5 Important Timeline
First edition of The Extra Pharmacopoeia.
Renamed Martindale: The Extra Pharmacopoeia.
Martindale Online launched.
Renamed Martindale: The Complete Drug Reference.
Online access through MedicinesComplete was introduced.
The 41st edition became the final print edition. The reference continues online.
8. Pharmacopoeial Monographs
A monograph is an official document that describes the quality requirements and testing procedures for a particular pharmaceutical substance, preparation or other article.
It defines the tests and acceptance criteria that an article must satisfy to comply with the relevant pharmacopoeial standard.
8.1 Main Components of a Monograph
- Official title: Name of the substance or preparation.
- Definition: Describes the substance or preparation and its required composition or content.
- Category or use: May provide relevant classification or use information.
- Description: Physical appearance or characteristics.
- Identification: Tests to confirm the identity of the substance.
- Tests: Quality-control tests such as pH, clarity, disintegration or dissolution, where applicable.
- Impurities: Limits and tests for specified impurities.
- Assay: Quantitative determination of the active substance.
- Storage: Storage conditions, where specified.
- Labelling: Additional labelling requirements, where applicable.
8.2 Types of Monographs
8.3 Example of a Drug Monograph
Consider a hypothetical tablet containing a specified quantity of a drug substance.
- Official name: Drug X Tablets.
- Definition: Tablets containing the specified amount of Drug X.
- Identification: Tests confirming the presence of Drug X.
- Uniformity: Compliance with applicable dosage-unit requirements.
- Dissolution: Compliance with the specified dissolution requirements.
- Assay: Drug content within the prescribed acceptance limits.
9. General Notices and General Chapters
9.1 General Notices
General Notices explain the rules, definitions and conditions used to interpret and apply the standards in a pharmacopoeia.
They provide instructions on how monographs, tests, assays and other requirements should be understood.
Important points:
- They apply broadly to the pharmacopoeia.
- They explain the meaning of official terms.
- They provide rules for interpreting monographs.
- They clarify the application of tests and acceptance criteria.
- Specific monograph requirements may take precedence when the General Notices permit or indicate this.
9.2 General Chapters
General chapters contain methods and procedures that may apply to multiple pharmaceutical substances and preparations.
Examples include:
- Dissolution test.
- Disintegration test.
- Uniformity of dosage units.
- Microbial limit tests.
- Sterility testing.
- Bacterial endotoxins test.
- Chromatographic procedures.
- Tests for particulate matter.
- Container and packaging requirements.
10. Important Quality Control Tests in Pharmacopoeia
10.1 Identification Test
Identification tests establish whether a given substance is the substance claimed. Common techniques include chemical reactions, infrared spectroscopy and chromatographic comparison.
10.2 Assay
An assay is a quantitative analytical procedure used to determine the amount or potency of the active ingredient in a pharmaceutical substance or preparation.
10.3 Limit Test
A limit test is a test designed to determine whether a particular impurity or contaminant is within the prescribed limit.
10.4 Dissolution Test
The dissolution test measures the rate and/or extent to which a drug substance goes into solution from a dosage form under specified conditions.
10.5 Disintegration Test
The disintegration test determines whether a tablet or capsule breaks down into smaller particles under specified experimental conditions.
10.6 Uniformity of Dosage Units
This test ensures that individual dosage units contain a consistent amount of drug within prescribed limits.
10.7 Sterility Test
The sterility test is used to determine whether a product complies with the pharmacopoeial requirements for absence of viable microorganisms under the specified test conditions.
10.8 Bacterial Endotoxins Test
This test detects or quantifies bacterial endotoxins in pharmaceutical products. It is particularly important for parenteral products.
| Test | What it checks |
|---|---|
| Identification | Correct identity of drug. |
| Assay | Amount or potency of drug. |
| Limit test | Specified impurity limit. |
| Dissolution | Release of drug into solution. |
| Disintegration | Breakdown of dosage form. |
| Uniformity of dosage units | Consistency between individual units. |
| Sterility | Compliance with sterility requirements. |
| Endotoxins | Bacterial endotoxin contamination. |
11. Important Pharmacopoeial Technical Terms
11.1 Official Drug
An official drug is an article included in an official pharmacopoeia and subject to its applicable standards.
11.2 Impurity
An impurity is an unwanted component present in a pharmaceutical substance or preparation apart from the intended substance and permitted formulation components.
11.3 Reference Standard
A reference standard is a well-characterised material used as a comparison material in analytical procedures to establish the identity, strength, quality or purity of a substance.
11.4 Primary Reference Standard
A primary reference standard is a reference material whose assigned characteristics are established without requiring comparison to another reference standard of the same type.
11.5 Secondary Reference Standard
A secondary reference standard is established or qualified by comparison with an appropriate primary reference standard and is used for routine analytical work when suitably qualified.
11.6 Reagent
A reagent is a chemical or material used in a chemical reaction or analytical test.
11.7 Assay versus Identification
| Identification | Assay |
|---|---|
| Confirms what the substance is. | Determines how much of the substance is present. |
| Primarily qualitative. | Quantitative. |
| Answers: Is it the correct drug? | Answers: Is the quantity or potency correct? |
12. Comparison of IP, BP, USP, NF and Extra Pharmacopoeia
| Feature | IP | BP | USP | NF | Extra Pharmacopoeia |
|---|---|---|---|---|---|
| Full name | Indian Pharmacopoeia | British Pharmacopoeia | United States Pharmacopeia | National Formulary | Martindale: The Complete Drug Reference |
| Country | India | UK | USA | USA | International reference work |
| First publication | 1955 (official first edition) | 1864 | 1820 | 1888 | 1883 |
| Publisher / authority | IPC | MHRA / BP Commission | USP Convention | USP Convention (current) | Pharmaceutical Press |
| Main purpose | Drug quality standards in India | Drug quality standards in UK | Drug quality standards in USA | Especially excipient standards | Comprehensive drug information |
| Legal nature | Official standards in India | Official standards in UK | Official compendium in USA | Official compendium in USA | Reference publication, not a statutory pharmacopoeia |
13. Important Differences: Pharmacopoeia vs Formulary
| Pharmacopoeia | Formulary |
|---|---|
| Primarily concerned with official quality standards. | Primarily provides information on medicines and their appropriate use. |
| Contains specifications and analytical tests. | May include indications, dosage, precautions and prescribing information. |
| Used in drug quality assessment and regulation. | Used to guide rational prescribing and medicine use. |
| Example: IP, BP, USP. | Example: National Formulary of India. |
14. International Pharmacopoeia and Other Pharmacopoeias
14.1 International Pharmacopoeia
- Published by the World Health Organization (WHO).
- First published in 1951.
- Provides recommended quality specifications and analytical methods for pharmaceutical substances and dosage forms.
- Promotes international harmonisation and access to quality medicines.
- It is not automatically a legally binding national pharmacopoeia in every country; legal effect depends on national adoption.
14.2 European Pharmacopoeia (Ph. Eur.)
- Developed under the European Pharmacopoeia Convention.
- Published by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
- Provides common quality standards for medicines and pharmaceutical substances in its member states and other participating countries.
- It is incorporated into the British Pharmacopoeia.
14.3 Japanese Pharmacopoeia (JP)
- Official pharmacopoeia of Japan.
- Published under the authority of the Ministry of Health, Labour and Welfare (MHLW).
- Provides standards for the quality of medicines used in Japan.
15. Important Examination Facts – One-Liner Revision
- First official edition of Indian Pharmacopoeia – 1955.
- First edition of British Pharmacopoeia – 1864.
- First edition of United States Pharmacopeia – 1820.
- First edition of National Formulary – 1888.
- First edition of Extra Pharmacopoeia – 1883.
- Original publisher of NF – American Pharmaceutical Association.
- Author of Extra Pharmacopoeia – William Martindale.
- Co-author of first Extra Pharmacopoeia – Dr. W. Wynn Westcott.
- Indian Pharmacopoeia Commission – Ghaziabad, Uttar Pradesh.
- IPC operates under – Ministry of Health and Family Welfare.
- IP is published by – Indian Pharmacopoeia Commission.
- IP 2022 – Ninth edition.
- IP 2026 – Tenth edition.
- First edition of IP was followed by supplement in – 1960.
- Second edition of IP – 1966.
- Third edition of IP – 1985.
- Fourth edition of IP – 1996.
- Fifth edition of IP – 2007.
- Sixth edition of IP – 2010.
- Seventh edition of IP – 2014.
- Eighth edition of IP – 2018.
- Ninth edition of IP – 2022.
- Tenth edition of IP – 2026.
- IP 2022 became effective – 1 December 2022.
- BP is generally published – Annually.
- BP is usually published in – August.
- BP becomes effective – 1 January of the following year.
- NF and USP combined under one cover – 1975.
- Current name of Extra Pharmacopoeia – Martindale: The Complete Drug Reference.
- Current online platform for Martindale – MedicinesComplete.
- Pharmacopoeia primarily establishes – Identity, purity, strength and quality.
Get important notes, MCQs, recruitment updates and mock-test information.
Join Telegram Channel Join WhatsApp ChannelHPRCA Pharmacy Officer – Online CBT Mock Test Series
10 CBT Tests with Answer Key
Practise exam-oriented questions and assess your preparation with Himexam.com.
START MOCK TEST NOWHPRCA Pharmacy Officer Mock Test Series – 10 CBT Tests with Answer Key
PHARMACOPOEIA – IMPORTANT MCQs
IP | BP | USP | NF | Extra Pharmacopoeia
Himexam.com
- A book containing only prescriptions and therapeutic guidelines
- An official or authoritative compendium containing standards for the quality of pharmaceutical substances and preparations
- A book dealing exclusively with drug manufacturing machinery
- A catalogue containing only brand names of medicines
- 1948
- 1960
- 1955
- 1966
- Indian Pharmacopoeia Commission
- Pharmacy Council of India
- World Health Organization
- Medical Council of India
- Mumbai, Maharashtra
- New Delhi
- Hyderabad, Telangana
- Ghaziabad, Uttar Pradesh
- 1820
- 1864
- 1883
- 1888
- 1888
- 1864
- 1820
- 1955
- 1888
- 1820
- 1864
- 1900
- John Snow
- Louis Pasteur
- Edward Jenner
- William Martindale
- National Formulary
- Extra Pharmacopoeia
- Indian Pharmacopoeia
- International Pharmacopoeia
- United States Pharmacopeial Convention
- World Health Organization
- American Pharmaceutical Association
- Food and Drug Administration
- First edition
- Third edition
- Fourth edition
- Second edition
- 1985 and 1996
- 1980 and 1990
- 1990 and 2000
- 1985 and 2000
- 1996
- 2005
- 2009
- 2010
- 1 January 2005
- 1 December 2007
- 1 January 2009
- 1 January 2010
- 1955 → 1966 → 1985 → 1996
- 1955 → 1985 → 1966 → 1996
- 1966 → 1955 → 1996 → 1985
- 1955 → 1960 → 1975 → 1985
- Sixth edition
- Seventh edition
- Ninth edition
- Eighth edition
- Seventh
- Ninth
- Eighth
- Tenth
- IP 2018
- IP 2022
- IP 2026
- IP 2024
- Four
- Two
- Three
- Five
- All such monographs automatically become invalid.
- They become recommendations only.
- They are transferred automatically to BP.
- They continue to be official as stipulated in the Second Schedule of the Drugs and Cosmetics Act, 1940.
- Indian Pharmacopoeia Commission
- United States Pharmacopeial Convention
- Medicines and Healthcare products Regulatory Agency
- World Health Organization
- January
- August
- March
- December
- 1 January 2027
- 1 August 2026
- 1 December 2026
- 1 January 2028
- It was published in January 2027.
- It has no legal status in the UK.
- It became effective on 1 January 2025.
- It remains the current legally effective edition through 31 December 2026.
- Indian Pharmacopoeia
- National Formulary
- European Pharmacopoeia
- Japanese Pharmacopoeia
- United States Pharmacopeial Convention
- Food and Drug Administration
- American Medical Association
- World Health Organization
- 1888
- 1938
- 1960
- 1975
- A publication containing only herbal medicines
- A combined publication containing USP and NF standards
- A WHO publication for developing countries
- A publication containing only clinical treatment protocols
- NF
- BP
- IP
- International Pharmacopoeia
- Only the British Pharmacopoeia
- Only the National Formulary
- United States Pharmacopeia and National Formulary
- Indian Pharmacopoeia and European Pharmacopoeia
- 1864
- 1883
- 1888
- 1900
- 1972
- 1984
- 1995
- 1999
- 41st edition, 2024
- 40th edition, 2020
- 42nd edition, 2025
- 39th edition, 2018
- To establish legally binding national impurity limits for all drugs
- To provide only official drug assay methods
- To provide comprehensive evaluated information about drugs and medicines
- To prescribe manufacturing licences
- MHRA
- WHO
- FDA
- IPC
- WHO
- MHRA
- FDA
- European Directorate for the Quality of Medicines & HealthCare
- Ministry of Health, Labour and Welfare, Japan
- World Health Organization
- United States Pharmacopeial Convention
- European Medicines Agency
- A list of all pharmaceutical companies
- A clinical case history of a patient
- A document containing quality specifications and applicable testing requirements for a particular article
- A document containing only the market price of a medicine
- Storage
- Identification
- Labelling
- Assay
- Disintegration
- Identification
- Sterility
- Assay
- Determine whether a specified impurity is within the prescribed limit
- Determine the exact therapeutic dose
- Measure the dissolution rate of every drug
- Identify the manufacturing equipment
- Uniformity of dosage units
- Disintegration
- Dissolution
- Identification
- Determining the drug’s chemical structure
- Determining whether the dosage form breaks down into smaller particles under specified conditions
- Measuring the exact amount of active ingredient
- Detecting bacterial endotoxins
- Friability test
- Disintegration test
- Hardness test
- Sterility test
- Parenteral preparations
- Ordinary oral tablets only
- Topical powders only
- Non-sterile oral syrups only
- Both tests measure exactly the same property.
- Disintegration determines drug potency, while dissolution determines microbial contamination.
- Disintegration measures breakdown of the dosage form, whereas dissolution measures drug release into solution.
- Dissolution is performed only for sterile products.
- To determine the retail price of a drug
- To act as a comparison material in an analytical procedure
- To replace the manufacturing licence
- To provide the patient’s clinical history
- A placebo
- A commercial advertisement
- A finished product label
- An appropriate primary reference standard
- They provide general rules and instructions for interpreting and applying pharmacopoeial requirements.
- They contain only the history of medicines.
- They list only the prices of pharmaceutical ingredients.
- They replace every individual monograph.
- Only an active antibiotic ingredient
- Only a therapeutic vaccine
- Magnesium stearate
- Only an active anticancer ingredient
- IPC is an autonomous institution under the Ministry of Health and Family Welfare.
- Its headquarters is located at Ghaziabad, Uttar Pradesh.
- It publishes the Indian Pharmacopoeia.
- It is the regulatory authority responsible for issuing all manufacturing licences in India.
- 1, 2 and 4 only
- 1, 2 and 3 only
- 2, 3 and 4 only
- 1, 3 and 4 only
- The first official edition was published in 1955.
- The second edition was published in 1966.
- The third edition was published in 1985.
- The fourth edition was published in 2007.
- 1 and 4 only
- 2 and 4 only
- 1, 2 and 4 only
- 1, 2 and 3 only
- BP was first published in 1864.
- BP is published annually.
- BP normally becomes effective on 1 January of the following year.
- BP excludes all European Pharmacopoeia texts.
- 1, 2 and 3 only
- 1 and 4 only
- 2, 3 and 4 only
- 1, 2, 3 and 4
- USP was first published in 1820.
- NF was first published in 1888.
- USP acquired NF in 1975.
- NF was originally published by WHO.
- 1 and 4 only
- 2 and 3 only
- 1, 2 and 3 only
- 1, 2, 3 and 4
- The first edition was published in 1883.
- William Martindale was associated with its first edition.
- Its 41st edition in 2024 was announced as the final print edition.
- It is a statutory pharmacopoeia of India.
- 1 and 4 only
- 1, 2 and 3 only
- 2, 3 and 4 only
- 1, 2, 3 and 4
- Assay determines the quantity or potency of a drug.
- Identification tests help confirm the identity of a substance.
- Dissolution measures drug release into solution under specified conditions.
- Disintegration and dissolution are identical tests.
- 1, 2 and 3 only
- 1 and 4 only
- 2 and 4 only
- 1, 2, 3 and 4
- Reference standards are used in analytical procedures.
- They can be used for identification and assay.
- A secondary reference standard is generally qualified against a primary reference standard.
- Reference standards are intended to be administered to patients.
- 1 and 4 only
- 2 and 3 only
- 1, 2, 3 and 4
- 1, 2 and 3 only
- Indian Pharmacopoeia
- British Pharmacopoeia
- United States Pharmacopeia
- National Formulary
- 1820
- 1888
- 1955
- 1864
- 1-d, 2-c, 3-b, 4-a
- 1-c, 2-d, 3-a, 4-b
- 1-a, 2-b, 3-c, 4-d
- 1-b, 2-a, 3-d, 4-c
- Assay
- Disintegration
- Dissolution
- Identification
- Confirmation of chemical identity
- Measurement of drug content or potency
- Breakdown of dosage form
- Drug release into solution
- 1-b, 2-c, 3-d, 4-a
- 1-a, 2-d, 3-b, 4-c
- 1-c, 2-a, 3-d, 4-b
- 1-d, 2-b, 3-a, 4-c
- IP 2007
- IP 1985
- IP 2014
- IP 1996
- 1 → 2 → 4 → 3
- 2 → 1 → 4 → 3
- 2 → 4 → 1 → 3
- 4 → 2 → 3 → 1
- Disintegration test
- Sterility test
- Identification test only
- Assay
- Identification test
- Dissolution test
- Uniformity of dosage units
- Disintegration test
- Sterility
- Uniformity of dosage units
- Identification of packaging
- Limit test for heavy metals only
- Both are statutory pharmacopoeias of India.
- Martindale contains only analytical standards, while pharmacopoeias contain only clinical information.
- A pharmacopoeia establishes official quality standards, whereas Martindale is a comprehensive drug information reference.
- There is no difference between them.
- A pharmacopoeial monograph may contain identification requirements.
- An assay is a quantitative procedure.
- General chapters may provide analytical procedures applicable to multiple monographs.
- Every test mentioned in every pharmacopoeial chapter automatically applies to every drug product, regardless of the relevant monograph and general notices.
- 1 and 4 only
- 2 and 4 only
- 1, 2, 3 and 4
- 1, 2 and 3 only
- IP is recognised as the official book of drug standards in India.
- BP and the European Pharmacopoeia have legal status within the UK.
- USP and NF have statutory recognition in the United States.
- Martindale is automatically a legally binding pharmacopoeia in every country.
- 1, 2 and 3 only
- 1 and 4 only
- 2 and 4 only
- 1, 2, 3 and 4
- They provide the market prices of medicines.
- They contain only historical information about drugs.
- They provide requirements applicable to a defined group or category of pharmaceutical articles.
- They replace all analytical procedures in individual monographs.
- To determine the selling price of the drug
- To compare chromatographic behaviour or response with a suitable reference material
- To replace the chromatographic instrument
- To determine the patient’s therapeutic response directly
- NFI is published by the Indian Pharmacopoeia Commission.
- It supports rational use of medicines.
- It is primarily a compendium of analytical impurity limits for every drug.
- It provides useful information for healthcare professionals regarding medicines and their use.
- 1 and 3 only
- 2 and 3 only
- 1, 2, 3 and 4
- 1, 2 and 4 only
- Martindale: The Complete Drug Reference
- Only a tablet disintegration monograph
- Only an impurity limit test
- A packaging specification alone
Important Final Revision
Remember the five major publication years:
USP – 1820 | BP – 1864 | Extra Pharmacopoeia – 1883 | NF – 1888 | First official IP – 1955.
Important current editions (November 2026):
IP 2026 – Tenth edition | BP 2027 – Published, effective from 1 January 2027 | BP 2026 – Current effective edition until 31 December 2026.
HPRCA Pharmacy Officer Online CBT Mock Test Series
10 CBT Tests with Answer Key
Practise exam-oriented questions and evaluate your preparation with Himexam.com.
START MOCK TEST NOWJoin Himexam Learning Communities
Get pharmacy notes, MCQ practice sets and important examination updates.
Join Telegram Channel Join WhatsApp Channelहमारे बारे में – Himexam.com
Himexam.com हिमाचल प्रदेश व अखिल भारतीय प्रतियोगी परीक्षाओं के लिए एक विश्वसनीय पोर्टल है। यहाँ आपको नवीनतम HP Govt Jobs, All India Jobs, HP GK, करेंट अफेयर्स, वन लाइनर प्रश्न, जिलेवार GK और पिछले वर्षों के प्रश्न पत्र की जानकारी एक ही जगह मिलती है। हमारी कोशिश है कि हर अभ्यर्थी को सही और समय पर अध्ययन सामग्री मिले।
📚 महत्वपूर्ण लिंक

Hello everyone! My name is Gaurav, My aim is to provide quality educational content, free study materials, and exam preparation resources to help students and job aspirants achieve their goals. I believe quality education should be accessible to everyone.





